Relmada Therapeutics, Inc. financial data

Symbol
RLMD on Nasdaq
Location
2222 Ponce De Leon Blvd. 3 Rd Floor, Coral Gables, FL
State of incorporation
NV
Fiscal year end
December 31
Former names
CAMP NINE, INC. (to 7/14/2014)
Latest financial report
10-K - Q4 2024 - Mar 27, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 638 % -43.1%
Return On Assets -124 % -46.3%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 33.2M shares +10%
Common Stock, Shares, Outstanding 30.2M shares +0.25%
Entity Public Float 89M USD +22%
Common Stock, Value, Issued 30.2K USD +0.25%
Weighted Average Number of Shares Outstanding, Basic 30.2M shares +0.21%
Weighted Average Number of Shares Outstanding, Diluted 30.2M shares +0.21%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 46.2M USD -15.7%
General and Administrative Expense 37.7M USD -22.9%
Operating Income (Loss) -83.9M USD +19.1%
Nonoperating Income (Expense) 3.91M USD -20.3%
Net Income (Loss) Attributable to Parent -80M USD +19%
Earnings Per Share, Basic -2.65 USD/shares +19.2%
Earnings Per Share, Diluted -2.65 USD/shares +19.2%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 3.86M USD -5.73%
Assets, Current 45.8M USD -53%
Other Assets, Noncurrent 22K USD -49%
Assets 45.8M USD -53%
Accounts Payable, Current 4.13M USD +17.8%
Accrued Liabilities, Current 6.16M USD -29.1%
Liabilities, Current 10.3M USD -15.6%
Liabilities 10.3M USD -15.6%
Retained Earnings (Accumulated Deficit) -641M USD -14.3%
Stockholders' Equity Attributable to Parent 35.5M USD -58.4%
Liabilities and Equity 45.8M USD -53%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -13M USD +21%
Net Cash Provided by (Used in) Financing Activities 222K USD
Net Cash Provided by (Used in) Investing Activities 10.1M USD -74.9%
Common Stock, Shares Authorized 150M shares 0%
Common Stock, Shares, Issued 30.2M shares +0.25%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 23.5M USD +4686%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 3.86M USD -5.73%
Deferred Tax Assets, Valuation Allowance 115M USD +4.74%
Preferred Stock, Shares Authorized 200M shares 0%
Additional Paid in Capital 676M USD +4.67%
Share-based Payment Arrangement, Expense 8.3M USD -26.9%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%